Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood–brain barrier

Judith Hauptmann, Lisa Johann, Federico Marini, Maja Kitic, Elisa Colombo, Ilgiz A. Mufazalov, Martin Krueger, Khalad Karram, Sonja Moos, Florian Wanke, Florian C. Kurschus, Matthias Klein, Silvia Cardoso, Judith Strauß, Subhashini Bolisetty, Fred Lühder, Markus Schwaninger, Harald Binder, Ingo Bechman, Tobias BoppAnupam Agarwal, Miguel P. Soares, Tommy Regen*, Ari Waisman

*Corresponding author for this work

Abstract

The proinflammatory cytokine interleukin 1 (IL-1) is crucially involved in the pathogenesis of multiple sclerosis (MS) and its animal model experimental autoimmune encephalomyelitis (EAE). Herein, we studied the role of IL-1 signaling in blood–brain barrier (BBB) endothelial cells (ECs), astrocytes and microglia for EAE development, using mice with the conditional deletion of its signaling receptor IL-1R1. We found that IL-1 signaling in microglia and astrocytes is redundant for the development of EAE, whereas the IL-1R1 deletion in BBB-ECs markedly ameliorated disease severity. IL-1 signaling in BBB-ECs upregulated the expression of the adhesion molecules Vcam-1, Icam-1 and the chemokine receptor Darc, all of which have been previously shown to promote CNS-specific inflammation. In contrast, IL-1R1 signaling suppressed the expression of the stress-responsive heme catabolizing enzyme heme oxygenase-1 (HO-1) in BBB-ECs, promoting disease progression via a mechanism associated with deregulated expression of the IL-1-responsive genes Vcam1, Icam1 and Ackr1 (Darc). Mechanistically, our data emphasize a functional crosstalk of BBB-EC IL-1 signaling and HO-1, controlling the transcription of downstream proinflammatory genes promoting the pathogenesis of autoimmune neuroinflammation.

Original languageEnglish
JournalActa Neuropathologica
Volume140
Issue number4
Pages (from-to)549-567
Number of pages19
ISSN0001-6322
DOIs
Publication statusPublished - 01.10.2020

Funding

Open Access funding provided by Projekt DEAL. The authors thank Michaela Blanfeld for technical assistance. This work was supported by the National Multiple Sclerosis Society (RG-1707-28780), the Sobek Foundation and the Hertie Foundation (P1150062) to A.W., and by Institutional Funding (Level I) of the University Medical Center Mainz to T.R. A.W., T.B. and M. Klein are members of the Research Center for Immunotherapy (FZI) Mainz. A.W. and T.B. were supported by the Deutsche Forschungsgemeinschaft (DFG) grants CRC/TRR128 and CRC1292. J.H. was supported by a fellowship from the Focus Program Translational Neuroscience (FTN) of the Johannes Gutenberg University Mainz. Financial support was also provided by the Gulbenkian and “La Caixa” (HR18-00502), Bill & Melinda Gates Foundation (OPP1148170) and FCT (5723/2014 and FEDER029411) to M.P.S. A.A. was supported in part by grants from the National Institutes of Health (R01 DK059600, P30 DK079337, and R01 DK118932). S.B. was supported by a grant from the National Institute of Health (K01 DK103931) and the American Society of Nephrology (Carl W. Gottschalk Research Scholar Grant).

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Research Areas and Centers

  • Academic Focus: Center for Infection and Inflammation Research (ZIEL)

Fingerprint

Dive into the research topics of 'Interleukin-1 promotes autoimmune neuroinflammation by suppressing endothelial heme oxygenase-1 at the blood–brain barrier'. Together they form a unique fingerprint.

Cite this